NCT06731478 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT06731478
Title	Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	No
Sponsors	Daiichi Sankyo
Indications	gastric adenocarcinoma gastroesophageal junction adenocarcinoma
Therapies	Capecitabine + Oxaliplatin + Trastuzumab Capecitabine + Oxaliplatin + Pembrolizumab + Trastuzumab deruxtecan Cisplatin + Fluorouracil + Trastuzumab Cisplatin + Fluorouracil + Pembrolizumab + Trastuzumab Capecitabine + Oxaliplatin + Pembrolizumab + Trastuzumab Capecitabine + Pembrolizumab + Trastuzumab deruxtecan Cisplatin + Fluorouracil + Pembrolizumab + Trastuzumab deruxtecan Fluorouracil + Pembrolizumab + Trastuzumab deruxtecan
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| ROU \| POL \| NOR \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG

No variant requirements are available.